$LXRP ---
Lexaria Bioscience Corp. (CSE:LXX; OTCQX:LXRP) is a research-driven company that has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.
Lexaria’s DehydraTECH™ technology is covered by issued and pending patents in over 40 countries around the world. Lexaria’s first patent was issued by USPTO in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Lexaria has applied for 60 patents that I am aware of, and 17 have already been approved.
First applications for the technology are being used in the legal cannabinoid consumer products space, which is expected to show Compounded Annual Growth Rate (CAGR) of more than 25% through 2021 in North America alone. Lexaria is also working with big tobacco companies to develop safer methods of delivering nicotine without the need of smoking, big pharma is looking at better methods of medicine delivery, and beverage and edibles are also showing very high interest.
In my opinion, the momentum is only just beginning. As more and more companies start exploring the many advantages of delivering their product ingredients by way of DehydraTech, we may see this technology expand exponentially. In the pharma industry, smaller doses are possible and that means far less negative side effects.
Kgem
Lexaria Bioscience Corp. (CSE:LXX; OTCQX:LXRP) is a research-driven company that has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.
Lexaria’s DehydraTECH™ technology is covered by issued and pending patents in over 40 countries around the world. Lexaria’s first patent was issued by USPTO in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Lexaria has applied for 60 patents that I am aware of, and 17 have already been approved.
First applications for the technology are being used in the legal cannabinoid consumer products space, which is expected to show Compounded Annual Growth Rate (CAGR) of more than 25% through 2021 in North America alone. Lexaria is also working with big tobacco companies to develop safer methods of delivering nicotine without the need of smoking, big pharma is looking at better methods of medicine delivery, and beverage and edibles are also showing very high interest.
In my opinion, the momentum is only just beginning. As more and more companies start exploring the many advantages of delivering their product ingredients by way of DehydraTech, we may see this technology expand exponentially. In the pharma industry, smaller doses are possible and that means far less negative side effects.
Kgem
2
